Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 9/20 | 0.62 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.55 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 5/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485463 | 0.94 | CACNA1B (0.65) | CACNA1BKCNT1KCNT2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3485740 | 0.91 | CACNA1B (0.61) | CACNA1BKCNT1KCNT2ALDH1A1KMT2A | |
| SCHEMBL13541735 | 0.89 | CACNA1B (0.55) | CACNA1BALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL3485553 | 0.84 | CACNA1B (0.57) | CACNA1BALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3485875 | 0.83 | CACNA1B (0.58) | CACNA1BCYP3A4NR1I2 | |
| SCHEMBL13541728 | 0.82 | CACNA1B (0.55) | CACNA1BALDH1A1SMN1; SMN2LMNATP53 | |
| SCHEMBL3485776 | 0.82 | CACNA1B (0.54) | CACNA1BALDH1A1LMNACYP3A4NR1I2 | |
| SCHEMBL3486130 | 0.82 | CACNA1B (0.54) | CACNA1BALDH1A1LMNACYP3A4NR1I2 | |
| SCHEMBL13543316 | 0.82 | CACNA1B (0.51) | CACNA1BKCNT1ALDH1A1KMT2AMEN1 | |
| SCHEMBL3484996 | 0.81 | ALDH1A1 (0.61) | CACNA1BALDH1A1KMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | CACNA1A, CACNA1E, CACNA1B | CACNA1B 3/4885KCNT1 104/4885KCNT2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.